6-(piperazin-1-yl)pyridine-2-carbonitrile | 909413-61-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 6-(piperazin-1-yl)pyridine-2-carbonitrile
• 英文别名: 6-piperazin-1-ylpyridine-2-carbonitrile
• CAS: 909413-61-2
• 化学式: C₁₀H₁₂N₄
• mdl: MFCD20367055
• 分子量: 188.232
• InChiKey: JMWVNEGUTLXDMG-UHFFFAOYSA-N

物化性质

• 沸点：
  400.2±40.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(piperazin-1-yl)pyridine-2-carbonitrile 在 potassium carbonate 、 一水合肼 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.75h， 生成 6-[4-(4-aminophenyl)piperazin-1-yl]pyridine-2-carbonitrile
  参考文献：
  名称：

  [EN] RADIOLABELED COMPOUNDS
  [FR] COMPOSÉS RADIOMARQUÉS

  摘要：

  本发明涉及式(I)的放射标记化合物，其中A、B、R1、R2中的任何一个用从3H、11C和18F中选择的放射性核素标记，并且其用于在哺乳动物中成像α-突触核蛋白和/或Abeta沉积物。

  公开号：

  WO2019121661A1
• 作为产物：
  描述：

  2-溴-6-氰基吡啶 在 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 6-(piperazin-1-yl)pyridine-2-carbonitrile
  参考文献：
  名称：

  [EN] PHENYL mTORC INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DE MTORC PHÉNYLE ET LEURS UTILISATIONS

  摘要：

  本发明提供了化合物、其组合物以及使用相同的方法。

  公开号：

  WO2018089433A1

文献信息

• PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES
  申请人：UCB Biopharma SPRL

  公开号：EP3527209A1

  公开（公告）日：2019-08-21

  The invention relates to 6,5 heterobicyclic ring derivatives, processes for preparing them, pharmaceutical compositions containing them and their use for the treatment of inflammatory conditions driven by STING activation, such as SLE and geographic atrophy.

  该发明涉及6,5杂环环衍生物，其制备方法，含有它们的药物组合物以及它们用于治疗由STING激活驱动的炎症性疾病，如SLE和地理性萎缩症。
• Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy
  作者：Wenhua Chen、Ne Guo、Minghui Qi、Haiying Dai、Minghuang Hong、Longfei Guan、Xiajuan Huan、Shanshan Song、Jinxue He、Yingqing Wang、Yong Xi、Xinying Yang、Yanyan Shen、Yi Su、Yiming Sun、Yinglei Gao、Yi Chen、Jian Ding、Yun Tang、Guobin Ren、Zehong Miao、Jian Li

  DOI：10.1016/j.ejmech.2017.06.053

  日期：2017.9

  Poly (ADP-ribose) polymerase 1 (PARP1) is overexpressed in a variety of cancers, especially breast and ovarian cancers, and tumor cell lines deficient in breast cancer gene 1/2 (BRCA1/2) are highly sensitive to PARP1 inhibition. In this study, with the help of molecular docking, we identified a novel series of 2,3-difluorophenyl-linker analogues (15-54) derived from olaparib (1) as PARPI inhibitors. Lead optimization led to the identification of 47, which showed high selectivity and high potency against PARP1 enzyme (IC50 = 13 nM), V-C8 cells (IC50 = 0.003 nM), Capan-1 cells (IC50 = 7.1 nM) and MDA-MB-436 cells (IC50 = 0.2 nM). Compound 47 had more potent PARPI-DNA trapping and double-strand breaks (DSBs)-induction activities than 1 and induced G2/M arrest and caspase-dependent apoptosis. Compound 47 (50 mg/kg, 94.2%) had a more beneficial effect on tumor growth inhibition than 1 (100 mg/kg, 65.0%) in a BRCA1-mutated xenograft model and significantly inhibited tumor growth (40 mg/kg, 48.1%) in a BRCA2-mutated xenograft model, with no negative influence on the body weight of the mice. Collectively, these data demonstrated that 47 might be an excellent drug candidate for the treatment of cancer, especially for BRCA-deficient tumors. (C) 2017 Elsevier Masson SAS. All rights reserved.
• RADIOLABELED COMPOUNDS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3728234A1

  公开（公告）日：2020-10-28
• Pharmaceutical 6,5 Heterobicyclic Ring Derivatives
  申请人：UCB Biopharma SRL

  公开号：US20200399268A1

  公开（公告）日：2020-12-24

  The invention relates to 6,5 heterobicyclic ring derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use for the treatment of inflammatory conditions driven by STING activation, such as, but not confined to, SLE and geographic atrophy.
• [EN] PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES<br/>[FR] DÉRIVÉS CYCLIQUES 6,5 HÉTÉROBICYCLIQUES PHARMACEUTIQUES
  申请人：UCB BIOPHARMA SPRL

  公开号：WO2019158731A1

  公开（公告）日：2019-08-22

  The invention relates to 6,5 heterobicyclic ring derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use for the treatment of inflammatory conditions driven by STING activation, such as, but not confined to, SLE and geographic atrophy.